Buffalo / Houston / Amsterdam / Toronto / Raleigh / New York / Chicago / Intermediate / /
Company
Astex Pharmaceuticals Inc. / Johnson and Johnson / Celgene / Incyte / /
Event
FDA Phase / /
Facility
Mohammad Azab10 Fels Institute / Temple University / University of Southern California / MD Anderson Cancer Center / University of Texas / Princess Margaret Hospital / Roswell Park Cancer Institute / Weill Cornell Medical College / University of Chicago Medical Center / Duke University Medical Center / /
IndustryTerm
treatment of relapsed/refractory acute myeloid leukemia / /
Congress / Princess Margaret Hospital / University of Southern California / Los Angeles / Mohammad Azab10 Fels Institute / Temple University / Philadelphia / Weill Cornell Medical College / Duke University Medical Center / Roswell Park Cancer Institute / USC Keck School of Medicine / University of Chicago Medical Center / University of Texas / /
Person
Jean Pierre / Karen Yee / Jean Pierre Issa / Elizabeth Griffiths / Gail Roboz / Mohammad Azab / Lisa Chen / Raoul Tibes / Mayo Clinic Arizona / David Rizzieri / Wendy Stock / /
Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory